Ventilator-induced lung injury is mediated, at least in part, by
TNF-alpha. We determined the effect of a recombinant human soluble
TNF receptor fusion
protein (
etanercept) on
mechanical ventilation (MV)-induced changes in a murine
ventilator-induced lung injury model. After pretreatment with
etanercept or placebo, C57Bl/6 mice were anesthetized and randomized to MV with either low tidal volumes (VT, approximately 7.5 mL/kg) or high VT ( approximately 15 mL/kg) for 5 h. Instrumented but spontaneously breathing mice served as controls. End points were
lung wet-to-dry ratios, lung histopathology scores,
protein levels, neutrophil cell counts and
thrombin-antithrombin complex levels in bronchoalveolar lavage fluid (BALF), and
cytokine levels in lung homogenates. The number of
caspase 3-positive cells was used as a measure for apoptosis.
Etanercept treatment attenuated MV-induced changes, in particular, in MV with high VT. Compared with placebo,
etanercept reduced the number of neutrophils in BALF and
thrombin-antithrombin complex levels in BALF and
cytokine levels in lung homogenates.
Lung wet-to-dry ratios, histopathology scores, and local
protein levels in BALF, however, were not influenced by
etanercept treatment. The number of
caspase 3-positive cells was significantly higher in
etanercept-treated animals. Inhibition of TNF by
etanercept attenuates, in part, MV-induced changes.